Viewing StudyNCT02773849



Ignite Creation Date: 2024-05-06 @ 8:36 AM
Last Modification Date: 2024-10-26 @ 12:02 PM
Study NCT ID: NCT02773849
Status: COMPLETED
Last Update Posted: 2023-12-22
First Post: 2016-04-19

Brief Title: ADSTILADRIN INSTILADRIN in Patients With High-Grade Bacillus Calmette-Guerin BCG Unresponsive Non-Muscle Invasive Bladder Cancer NMIBC
Sponsor:
Organization: Ferring Pharmaceuticals

Study Design

Study Type: INTERVENTIONAL
Expanded Access Type Individual: None
Expanded Access Type Intermediate: None
Expanded Access Type Treatment: None
Patient Registry: None
Target Duration: None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention: None
Bio Spec Description: None
Enrollment Count: 157
Enrollment Type: ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
Name
PHASE3
Observational Models:
Time Perspective List:
Who Masked List: